Business
Posting of Circular & Notice of GM
Posting of Circular & Notice of GM.
About this update from Renalytix Plc
[{"type":"text","content":"\n\nRenalytix plc\n(\"Renalytix\" or the \"Company\")\n \nPosting of Circular\nand\nNotice of General Meeting\n \nLONDON and NEW YORK, 11 October, 2024 ̶ Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, confirms that, further to the Company's announcement released at 11:02 on 1 October 2024 (RNS Number: 4887G), the Circular, containing the Notice of the General Meeting, which sets out the Resolutions and further details on the Fundraising, has been posted to Shareholders and is available on the Company's website at https://renalytix.com.\n \nThe General Meeting to approve the Resolutions will be held at 6 Stratton Street, Mayfair, London, W1J 8LD at 12.00 noon on 31 October 2024.\n \nThe Circular includes a unanimous Board recommendation that all Shareholders of the Company vote in favour of the Resolutions.\n \n \nFor further information, please contact:\n \n\n\n\n\nRenalytix Plc\nJames McCullough, CEO\n \n\n\nwww.renalytix.com\nVia Walbrook PR\n\n\n\n\nStifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)\nNicholas Moore / Nick Harland / Ben Good\n \n\n\nTel: 020 7710 7600\n \n\n\n\n\nOberon Capital (Joint Broker and Sole Bookrunner)\nMike Seabrook / Nick Lovering / Jessica Cave\n \n\n\nTel: 020 3179 5300\n \n\n\n\n\nWalbrook PR Limited\nPaul McManus / Alice Woodings\n\n\nTel: 020 7933 8780 or [email protected]\nMob: 07980 541 893 / 07407 804 654\n \n\n\n\n\nCapComm Partners\nPeter DeNardo\n\n\nTel: 415-389-6400 or [email protected]\n \n\n\n\n\n\n\n\n\n\n \nThe person responsible for making this Announcement on behalf of the Company is\nJames McCullough, Chief Executive Officer.\n \nAbout Renalytix plc\nRenalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence enabled in-vitro diagnostics and laboratory services company that is the global founder and leader in the field of bioprognosis™ for kidney health. In late 2023, our kidneyintelX.dkd test was recognized as the first and only FDA-authorized prognostic test to enable early-stage CKD (stages 1-3b) risk assessment for progressive decline in kidney function in T2D p...